TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05163275

Intervention type: DIAGNOSTIC_TEST
Intervention: Video recording and EMG
Description: The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total
Study: NCT05933174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prompt-sheet
Description: Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual education
Description: Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
Study: NCT05944783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 100 MG
Description: single dose of 100 mg Dasatinib tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 100 MG
Description: single dose of 100 mg Dasatinib tablets
Study: NCT06660381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a moderately high dose (25mg) of psilocybin in week 5 of the 12-week counseling, and either another moderately high dose (25mg) or a high dose (35mg) in week 7.
Study: NCT06665191

Intervention type: OTHER
Intervention: No Intervention: Observational study for prevalence of dental wear and its association with quality of life
Description: not applicable as it is an observational study testing the prevalence of dental wear in patients attending Cairo University
Study: NCT06665165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0114
Description: Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06475001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC).~VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator without active ingredient
Study: NCT06665958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose
Study: NCT06666413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa
Description: Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion
Study: NCT06140355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily 2 min pain management survey
Description: Completing one short survey (2 min) daily through your phone or computer (you will get a survey link through email or text), with a 6-month follow-up.
Study: NCT06666556

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bowel preparation before colonoscopy
Description: In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bowel preparation before colonoscopy
Description: In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
Study: NCT06665087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrafractionated RT and CGA Guided systemic treatment.
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated Radiotherapy
Description: 1Fx every 3 or 4weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Sintilimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Fluorouracil)
Description: 5-Fluorouracil or capecitabine

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Fluorouracil)
Description: 5-Fluorouracil or capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Raltitrexed)
Description: Raltitrexed

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Raltitrexed)
Description: Raltitrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Oxaliplatin)
Description: Oxaliplatin

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Oxaliplatin)
Description: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CPT-11)
Description: Irinotecan

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (CPT-11)
Description: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy (anti-VEGF)
Description: anti-VEGF antibody

Intervention type: DRUG
Group type: OTHER
Intervention: Targeted Therapy (anti-VEGF)
Description: anti-VEGF antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy (anti-EGFR)
Description: anti-EGFR antibody

Intervention type: DRUG
Group type: OTHER
Intervention: Targeted Therapy (anti-EGFR)
Description: anti-EGFR antibody
Study: NCT06595303

Intervention type: DRUG
Intervention: Nitrous oxide for labour analgesia
Description: Any woman may choose to have nitrous oxide inhalation as a standard protocol for labour analgesia
Study: NCT06667401

Intervention type: DEVICE
Intervention: The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia
Description: The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia.We also aim to see of how it enhances teaching and training of residents by experienced regional anesthesia providers. We intend to use surveys/questionnaires of both resident and regional anesthesia provider as they utilize the device in real time.
Study: NCT06667219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A relevant physical fitness training program intervention
Description: 54children who participated in after-school sports activities in Guangzhou Kindergarten (Guangzhou, China) were randomly selected as the experimental group.~Intervention group Length:12 weeks, 40 minutes, twice a week.~Intervention content:~The intervention will be conducted using a relevant physical fitness training program , as follows: Week 1 / 4 first: Run quickly;Durian ball;Throw;Fast jogging (200 m) Week 1 / 4 second: Dodge run,Raise your legs high and go over the small hurdles; Durian ball (standing on one foot);standing long jump Week 2 / 5 first: Bow step transformation jump;Throw;Turn back 10 meters Week 2 / 5 second: Hop ;Stand on one foot with your eyes open Week 3 / 6 first:Skip over the small hurdles;Durian ball (standing on one foot);Throw; Fast jogging (200 m) Week 3 / 6 second:Jump on your feet and dodge running;Durian ball (squat);Jump support Weeks 7-12,Repeat the above content. FMS index was tested before the experiment, and once after the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group,Physical exercise using kindergarten standards
Description: 54 children who did not participate in after-school sports activities were selected as the control group.~control group Duration: 12 weeks. Content: Physical exercise using kindergarten standards. FMS index was tested the same to intervention group before the test and FMS index was measured once again after 12 weeks.
Study: NCT04731155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor （Alirocumab）plus standard medications
Description: PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medications
Description: standard medications was giving to subjects according guidelines
Study: NCT04905277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol 50 MG
Description: 50 mg Atenolol daily
Study: NCT06665646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hiltonol
Description: Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO)
Study: NCT06664905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 Repetition Maximum (RM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 Repetition Maximum (RM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 Repetition Maximum (RM)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: No exercise
Study: NCT06667063

Intervention type: OTHER
Intervention: Nasal swab/Nasopharyngeal swab/Blood sample collection
Description: Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing

Intervention type: OTHER
Intervention: Nasal swab/Nasopharyngeal swab/Blood draw
Description: Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing

Intervention type: OTHER
Intervention: Nasal swab/Nasopharyngeal swab/Blood draw
Description: Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
Study: NCT05845021

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Surgeon-Initiated Bone Health Referral Pathway
Description: Described in arm description
Study: NCT04905277

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo daily
Study: NCT06054230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genomic Sequencer
Description: Genomic Sequencing Device
Study: NCT04513613

Intervention type: DEVICE
Intervention: Procedure/Surgery: Robotic-PVI
Description: Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
Study: NCT06676475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: 2ml MgSo4 (Magnesium sulfate sterile ampoule 10 ml, 100 mg/ml = 0.41 mMol/ml. Egyptian Int. Pharmaceutical Industries Co., Egypt).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX-A
Description: 2ml of BTX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: 2 ml of saline
Study: NCT06614543

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal Replacement
Description: These meal replacements provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.
Study: NCT05283902

Intervention type: BIOLOGICAL
Intervention: ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
Description: In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.

Intervention type: BIOLOGICAL
Intervention: ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
Description: In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.

Intervention type: BIOLOGICAL
Intervention: ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
Description: In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
Study: NCT06620731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c capsule
Description: Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c capsule
Description: Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c capsule
Description: Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.
Study: NCT06685653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adebrelimab+RGL-270
Description: Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adebrelimab+RGL-270/single RGL-270
Description: Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines
Study: NCT06685081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 0.25 µg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 0.5 µg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 0.75 µg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 1 µg/kg
Study: NCT05493423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V Needle AV Fistula Set
Description: Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
Study: NCT06685081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and triamcinolone
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and triamcinolone
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and triamcinolone
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and triamcinolone
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and triamcinolone
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection
Study: NCT06684795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG001 prior to surgery
Description: Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG001 prior to surgery
Description: Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
Study: NCT06684210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal plane block of the external oblique muscle
Description: Under ultrasound guidance, a single dose of 0.25% ropivacaine 20ml was given for bilateral intercostal muscle plane block of external oblique muscles
Study: NCT06683430

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Potassium, Low Sodium Diet
Description: Daily intake of 3500 mg K and 1500 mg Na for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Diet
Description: Daily intake of 1700 mg K and 2000 mg Na for 14 days.
Study: NCT06685133

Intervention type: DEVICE
Intervention: Robotic assisted bronchoscopy
Description: Subjects will undergo a robotic navigated bronchoscopy to biopsy peripheral pulmonary nodules.
Study: NCT06684392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Subjects will train only inspiratory muscle strength if they do not achieve VP or definitive disconnection of MV, and, when they already achieve these VP or definitive disconnection, the new EMI regimen that combines strength and resistance training will begin to be applied. Inspiratory muscle training guideline (EMI). On the day that, according to the EMI guideline, the Pimax evaluation corresponds, the training time will be replaced by the evaluation to avoid overloading the subjects with ventilatory work, training them only once a day.
Study: NCT06682026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music or chatting
Description: Written consent will be obtained from the patients just before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be applied to all participants.~Women in the experimental group will be asked to listen to a lively music of their own choosing during the mammography, or for those who do not want music, their attention will be drawn in a different direction by chatting.~At the end of the procedure, the Visual Acuity Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups.
Study: NCT06682936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ambulatory chest drain and talc pleurodesis
Description: a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
Study: NCT06368986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 administered in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 administered in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 administered in fasted or fed conditions.
Study: NCT06685367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acura AKI
Description: When the AI algorithm (Acura AKI) identifies a high-risk AKI patient, nephrologists and ICU pharmacists will receive an alert message. Upon receiving the alert, they will review the patient's electronic health record and make treatment suggestions based on AKI bundle care protocols. They will also coordinate with the patient's primary care team to ensure that the recommendations are implemented